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Abstract 
Objective: To identify the most cost-effective policy for detection and management of fetal 
macrosomia in late-stage pregnancy. 
 
Design: Health economic simulation model. 
 
Setting: All English NHS antenatal services. 
 
Population: Nulliparous women in the third trimester treated within the UK NHS. 
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Methods: A health economic simulation model was used to compare long-term maternal-fetal 
health and cost outcomes for two detection strategies (universal ultrasound scanning at 
approximately 36 weeks gestational age versus selective ultrasound scanning), combined with three 
management strategies (planned caesarean section versus induction of labour versus expectant 
management) of suspected fetal macrosomia. Probabilities, costs and health outcomes were taken 
from literature. 
Main Outcome Measures: Expected costs to the NHS and Quality-adjusted life years (QALYs) gained 
from each strategy, calculation of net benefit and hence identification of most cost-effective 
strategy. 
 
Results: Compared to selective ultrasound, universal ultrasound increased QALYs by 0.0038 (95% CI: 
0.0012, 0.0076), but also costs by £123.5 (95% CI: 99.6, 149.9). Overall, the health gains were too 
small to justify the cost increase. The most cost-effective policy was selective ultrasound coupled 
with induction of labour where macrosomia was suspected. 
 
Conclusions: The most cost-effective policy for detection and management of fetal macrosomia is 
selective ultrasound scanning coupled with induction of labour for all suspected cases of 
macrosomia. Universal ultrasound scanning for macrosomia in late-stage pregnancy is not cost-
effective. 
 
Funding: National Institute for Health Research (NIHR) 
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health economics 
 
Tweetable abstract: Universal late-pregnancy ultrasound screening for fetal macrosomia is not 
warranted 
 
Introduction 
The detection and management of macrosomia, i.e. excessive fetal growth, poses a challenge to 
maternity care. Macrosomia is associated with increased perinatal mortality and morbidity, e.g. 
shoulder dystocia leading to brachial plexus injury (BPI), as well as increased risk of maternal 
morbidity. 1-3 The definition of macrosomia varies, but is usually defined as a birth weight above 
either 4000g or 4500g. It is differentiated from, but closely related to, the concept of large for 
gestational age (LGA) which is a relative measure: weight greater than the 90th percentile for a given 
gestational age.1, 4 Macrosomia can only be definitively diagnosed by weighing the infant following 
delivery. However, ultrasound scans can be used to estimate the fetal weight antenatally, although 
this approach is known to have low predictive value. 1 There is no general agreement on how to 
manage macrosomia if suspected following ultrasound.1, 4-6 Possible interventions include scheduling 
an elective caesarean section (CS), or early induction of labour. However, uncertainty regarding the 
clinical effectiveness of these interventions persists.1, 5 Furthermore, if given without clinical need, 
intervention may cause unnecessary harm, e.g. neonatal respiratory morbidity, and increased 
maternal risks of caesarean section.1, 4, 7, 8 
There is currently no national programme that couples screening for macrosomia with a proven, 
disease modifying intervention.4, 9 Currently, clinical examination of third-trimester pregnancies does 
not routinely include ultrasound, but women may be selected for ultrasound scanning following 
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clinical suspicion of macrosomia (selective ultrasound). An alternative approach would be to 
prospectively scan all women for macrosomia (universal ultrasound) at around 36 weeks gestational 
age, but whether the benefits of such an approach would justify the increased costs and risk of 
harmful interventions is unclear. A previous study showed only modest health benefits from 
universal ultrasound, and the cost for every prevented severe adverse outcome was too high to 
justify routine scanning.10 However, this study is now over 20 years old and only considered one 
management strategy for suspected macrosomia: delivery by planned CS. Following recent research 
and changes in obstetric care, we sought to re-evaluate the case for universal ultrasound screening 
for macrosomia.11 
In this study, we identify the most cost-effective strategy for detection and management of 
macrosomia in late pregnancy among nulliparous women in the setting of the UK NHS. 
Methods 
Model structure 
The scope of this model was limited to screening for macrosomia rather than any other complication 
of pregnancy. To compare the cost-effectiveness of different policies for detection and 
management, we constructed a decision tree simulation model using R (Figure 1).12-14 Each policy 
had two components: one for the detection of macrosomia, and one for the management of 
suspected macrosomia. The detection strategy was either universal ultrasound in the third trimester 
(around 36 weeks gestational age), or selective ultrasound, i.e. clinical examination through 
abdominal palpation, where ultrasound would be offered only where macrosomia was suspected. 
The management strategy for suspected macrosomia was either to schedule an elective caesarean 
section (Planned CS), induce labour (Induction), or expectant management awaiting spontaneous 
labour onset. If macrosomia was not suspected, expectant management was used. There are 
therefore a total of six discrete detection/management policies. 
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The model structure for detection and management for macrosomia is shown in Figure 1 (part A). 
Four different screening statuses were possible: true positives (TP), false negatives (FN), false 
positives (FP), and true negatives (TN). The likelihood of each state was driven by the sensitivity and 
specificity of the test used for detection, as well as the prevalence of macrosomia. When 
macrosomia was suspected, the pregnancy was managed according to the management strategy 
being evaluated: planned caesarean section, induction of labour, or expectant management. If 
macrosomia was not suspected, it was assumed vaginal delivery would be attempted, with a risk of 
emergency caesarean section. To accurately capture the consequences of a false positive diagnosis 
of macrosomia, we distinguished between expectant management when macrosomia was suspected 
or not suspected; suspected macrosomia increased the risk of caesarean delivery following 
expectant management.8 
Five neonatal delivery outcomes were possible: No complications, Respiratory morbidity, Shoulder 
dystocia, Other acidosis (i.e. acidosis not induced by shoulder dystocia), and perinatal mortality. 
Their respective likelihoods were affected by both screening and management strategies (see 
below). The fetal delivery outcomes were then extrapolated into long-term costs and quality-
adjusted life years (QALYs) through the model shown in Figure 1.  
 
Model inputs 
Probabilities 
For each adverse outcome (respiratory morbidity, shoulder dystocia, other acidosis, and mortality), 
we obtained the baseline risk of that outcome; i.e. the risk if non-large and non-induced neonate 
with vaginal delivery. We then multiplied this risk with the relative risk of each present risk factor 
(macrosomia, induction, delivery through elective caesarean section, and delivery through 
emergency caesarean section). For technical details, see Appendix S1. 
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Model input parameters are shown in supplementary material Table S1. Values were identified from 
literature by AM and DW, prioritising values from systematic reviews and UK data where possible. 
Ideally, every input should be based upon a systematic review, reflecting current state of knowledge. 
However, resources only permitted identification of suitable data, rather than performing a meta-
analysis. For this reason, sources that provided a distribution for the likely parameter values were 
prioritized, so that the overall uncertainty associated with this parameter could be assessed through 
probabilistic sensitivity analysis.15 Where multiple sources were available the source was chosen by 
consensus or through arbitration by GS,.. Where no credible values for a model parameter could be 
identified from the literature, AM and GS identified lower and upper limits to the value the 
parameter could reasonably assume; the model then sampled input values from this interval using a 
uniform distribution. 
Macrosomia was defined as estimated fetal weight (EFW) ≥ 90th percentile, i.e. the same as large for 
gestational age (LGA). The sensitivity and specificity for detection of macrosomia, as well as the 
prevalence of macrosomia, were taken from the POP study, a prospective cohort study of unselected 
nulliparous women where all women had fetal biometry at 36 weeks of gestational age (wkGA), 
where the result of the scan was blinded.16, 17 Using data from this study allowed for a comparison 
between diagnostic performance of universal and selective ultrasound. Detection with selective 
ultrasound was based upon clinical suspicion before 36 wkGA following measurement of 
symphyseal-fundal height, and confirmed with a clinically indicated ultrasound.17 The baseline risk of 
each adverse outcome was defined as the risk for a normal size neonate, where labour was not 
induced and resulted in a vaginal delivery. We used odds ratios from the literature when directly 
presented, otherwise we calculated unadjusted odds ratios from prevalence data.18 Odds ratios were 
assumed log-normally distributed.  
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Long-term outcomes 
Unit costs and health state utilities are shown in supplementary material Table S1. The average costs 
for induction of labour and respiratory morbidity were calculated from the NHS reference costs (see 
Appendix S2).19 Brachial Plexus Injury (BPI) could be either transient or permanent, this was 
modelled using Beta distribution.20 We assumed that BPI would require the same resource usage as 
reported by Culligan et al., and obtained the costs for these resources from the NHS reference costs 
(see Appendix S2).19, 21 We assumed that all cases of non-severe asphyxia would be treated in the 
neonatal unit for 1-3 days, but that no additional costs would accrue beyond this. To estimate the 
long-term outcomes from ‘Severe anoxic brain damage’, we made the simplifying assumption that 
the costs, consequences and likelihood mirrored those of neonatal encephalopathy (NE). Evidence 
shows that providing therapeutic hypothermia reduces the likelihood of adverse outcomes from NE 
and this treatment is routine clinical practice.22, 23 We assumed that all cases of NE would receive 
therapeutic hypothermia, and adjusted costs and consequences from NE accordingly; for this reason, 
we reduced the likelihood of mortality and severe anoxic brain damage following asphyxia by 
11.1%.24 The costs from severe anoxic brain damage included hospital and community care costs for 
all survivors in the cooled group as reported by Regier et al. (2010)22; the hospital costs were for the 
first 18 months only, but we assumed that the community care costs post discharge would accrue 
annually for the entirety of the model’s time horizon. We made the simplifying assumption that the 
cost of death would be the same regardless of reason. 
Quality-adjusted life years (QALYs) combine the utility of a health-state with its duration, where 
utility is based upon quality of life (QOL). QOL can be expressed as a numeric value, where 1 is 
equivalent to full health and 0 equivalent to death.25, 26 Maternal QALYs were based upon the mode 
of delivery, and QOL weights were obtained from Petrou et al.27; these QOL weights were derived 
using EQ-5D, as recommended by NICE.28, 29 For surviving infants, we calculated the expected QALYs 
based upon the assumptions above; per definition fetal QALYs were zero for death. 
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Model scope 
The expected cost and QALYs gained from six different policies for screening and management of 
macrosomia were calculated over a 20-year time horizon. Costs and QALYs were discounted by 3.5% 
annually, as recommended by NICE.29 Probabilistic sensitivity analysis (PSA) was used in order to 
capture the overall effect of uncertainty in the model parameters. Costs associated with potential 
litigation claims or potential effects upon subsequent pregnancies were not included. Results were 
based upon 100,000 simulations and results presented as expected values, incremental cost and 
QALYs, incremental cost-effectiveness ratios (the ratio of incremental cost to incremental QALYs; 
ICER), and net benefits (defined as QALYs multiplied by the willingness to pay (WTP) for a QALY less 
the cost). The WTP per QALY threshold was assumed to be £20,000 (the lower of NICE’s stated 
thresholds).29 Decision uncertainty is illustrated via cost-effectiveness acceptability curves (CEACs).29, 
30 The model’s sensitivity towards key parameters was explored through one-way sensitivity analysis 
(see Appendix S4). Given the paucity of data relating to maternal quality of life, an additional 
scenario was conducted including neonatal QALYs alone. Further scenarios explored the impact of 
assigning zero additional costs for induction of labour, and assuming that induction of labour is cost 
saving (due to reduced antenatal assessments). .29, 30 All costs are from the third-party payer (i.e. 
NHS) perspective, and the price year is 2016/17. Costs from other years were inflated to the price 
year of the analysis using the hospital & community health services (HCHS) index.31 As this is a 
secondary analysis / synthesis of existing data, no patients or the public were involved in the study. 
Results 
The expected costs and quality-adjusted life years (QALY) for each policy are shown in Table 1. The 
least expensive option is selective ultrasound with expectant management and the most expensive 
option is universal ultrasound with planned CS. The least effective option (in terms of QALYs gained) 
is universal ultrasound with planned CS and the most effective option is universal ultrasound with 
induction of labour. Three strategies (selective US + planned CS, universal ultrasound + expectant 
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management, and universal ultrasound + planned CS) are dominated or extended-dominated by 
other strategies. Taking into account the balance between costs and outcomes (and with a WTP 
threshold of £20,000 per QALY), the most cost-effective strategy is selective ultrasound plus 
induction of labour where macrosomia is suspected. Although universal ultrasound plus induction is 
expected to yield marginally greater QALYs (+0.002), the added cost (+£113) yields an ICER of 
£52,719. This is above the threshold and is not, therefore, cost-effective. The expected distribution 
of mode of delivery and neonatal delivery outcomes are detailed in Appendix S3 and Table S2. 
We investigated the value of universal ultrasound alone, by comparing the results for universal and 
selective ultrasound when using the same management strategy. When the management strategy 
was planned CS, universal ultrasound was associated with a cost increase of £123.5 (95% Confidence 
interval: £99.6, £149.9), and QALY increase of 0.0038 (95% CI: 0.0012, 0.0076). The ICER for this 
strategy was £35,755 (95% CI: £15,962, £98,506). The comparable ICERs for induction of labour and 
expectant management were even higher, indicating that universal ultrasound screening is unlikely 
to be cost-effective. 
The probability of each policy being the most cost-effective as a function of the WTP-threshold is 
shown by the CEAC (Figure 2). Selective ultrasound coupled with induction of labour for suspected 
macrosomia had the greatest chance of being cost-effective for NICE’s recommended thresholds of 
£20,000 to £30,000 per QALY.29 Sensitivity analysis showed that the choice of policy was most 
sensitive towards the specificity of ultrasound (both universal and selective), maternal quality of life 
(QOL) for delivery through elective CS, and the prevalence of macrosomia (See Appendix S4 and 
Table S3). Although influential, the cost of ultrasound screening alone appears insufficient to 
determine whether universal screening would be cost-effective; analysis showed that if other 
parameters remained unchanged, universal ultrasound would only be cost-effective if the cost of 
ultrasound was £26.56 or lower. 
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Excluding maternal QALYs from the analysis, selective ultrasound plus planned CS was the preferred 
management strategy, compared with induction of labour, under the base case (Table S4). No other 
assumptions tested in the alternative scenarios affected the conclusions; selective ultrasound with 
induction of labour remained the preferred strategy for all other scenarios. 
Discussion 
Main findings 
This study has compared the cost-effectiveness of different policies for detection and management 
of fetal macrosomia in late-stage pregnancy among nulliparous women. The most cost-effective 
policy was selective ultrasound coupled with induction of labour for all cases of suspected fetal 
macrosomia. Although universal ultrasound scanning leads to higher identification of suspected 
macrosomia, this only translates into modest improvements of overall long-term health outcomes 
which are not justified by the added cost of the ultrasound scan. The expected health gain (0.003 
QALYs over 20 years) is small due to both the low risk of severe neonatal outcomes resulting from 
undiagnosed macrosomia and the risk of interventions themselves causing harm.   
Where macrosomia is suspected following ultrasound scanning, intervention is generally preferred 
to awaiting spontaneous labour onset. Although currently subject to further research32, this study 
found that induction of labour is the preferred intervention. However, it is worth noting that from 
the infant’s perspective alone, the best option is an elective caesarean section (Table S4, scenario 
“Maternal QALYs excluded”). 
Universal (rather than selective) ultrasound coupled with induction of labour has the potential to be 
the most cost-effective policy, but only at very high valuations of health gain: the small added 
benefit does not currently justify the cost. Sensitivity analysis shows that the relative cost-
effectiveness of the policies is sensitive to changes in the cost of ultrasound scanning, as well as the 
costs of caesarean section and induction of labour, and the sensitivity and specificity of ultrasound 
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scanning. Thus if the cost of the scan falls substantially in the future, a universal scanning policy 
could be cost-effective; analysis shows that this would happen at a cost lower than £26.56 (a cost 
reduction by 74.4%). Further, macrosomia is not the only fetal complication that can be assessed 
through ultrasound screening, thus when combined with a scan for other anomalies, such as breech 
presentation, the marginal cost of detecting macrosomia may be sufficiently low to render the 
overall policy cost-effective. However, further work is needed to explore this. 
 
Strengths and Limitations 
The strength of this study is that it evaluates strategies for both detection and management of fetal 
macrosomia jointly. There has been a lack of studies evaluating screening strategies coupled with 
clear evidence-based interventions. Economic modelling allows us to estimate how neonatal and 
maternal health outcomes would be affected if ultrasound screening were to be routinely 
implemented in clinical practice. However, the robustness of the conclusions are only as strong as 
the data available to inform them. Indeed, many parameters were informed by a single study, and 
where no data were available we relied on expert opinion. Critically, as a part of this process we 
elicited a range of plausible values to represent the inherent uncertainty. The probabilistic sensitivity 
analysis incorporates this uncertainty to determine how much it affects the overall results. 
We have limited our analysis to nulliparous women. It is unclear whether our findings could be 
extended to parous women as well, especially given the absence of data on screening performance 
for universal and selective ultrasound for this group. The economic modelling also relies upon 
simplifying assumptions regarding the long-term outcomes from the mode of delivery and fetal 
delivery outcomes and did not take account of alterations to planned place of birth following 
ultrasound. The interplay between fetal macrosomia and long-term outcomes may be too complex 
to capture entirely within our model; macrosomia can lead to more complications than those 
explored in this analysis. However, in the absence of more detailed data on many of these 
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complications, this model is still based upon the best current understanding of macrosomia and its 
consequences. 
The probability of delivery outcomes in this analysis relied upon the assumption of no interaction 
between macrosomia and the intervention. In reality, this assumption may not hold perfectly; for 
example, elective caesarean section may yield a greater relative risk reduction for babies with 
macrosomia. However, data limitations made the assumption necessary in order to model the 
relevant outcomes, especially given the many different sources used for parameters. Also, the 
relative risk associated with both macrosomia and interventions were included in the analysis, even 
though interactions were not modelled. 
 
Interpretations 
Our conclusion that universal ultrasound screening for fetal macrosomia is not cost-effective aligns 
with previous findings for macrosomia management based upon ultrasound screening.10 Universal 
ultrasound screening strategies were less cost-effective than selective ultrasound for all scenarios. 
Our analysis demonstrated that universal ultrasound is associated with improved health outcomes, 
but that these gains are too small to justify its added cost. 
This analysis is based in a UK NHS setting. The results will be generalisable to other settings with 
similar management policies and relative costs: current UK practice is to offer a scan at first and 
second trimester but only offer late pregnancy scans where clinically indicated (our ‘selective 
ultrasound’ policy). Many European countries perform a third scan around 32 weeks.33 Diagnostic 
effectiveness at 32 weeks for predicting complications related to macrosomia at delivery is likely to 
be poorer than at the 36-7 weeks assumed in our analysis, given the longer interval between the 
scan and timing of birth.16 This would suggest earlier scans are even less likely to be cost-effective. 
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As stated above, the impact of caesarean section (CS) on maternal quality of life was a key driver of 
the results. To the best of our knowledge, the study by Petrou et al.27 is the only study that reports 
maternal quality of life (QOL) as a function of the mode of delivery, using an adequate time horizon 
and a measure for QOL recommended by NICE.29 However, it reported lower QOL for women who 
underwent elective CS than their counterparts who delivered through emergency CS, a finding that 
appears counterintuitive. If maternal QOL had been higher following elective CS than emergency CS, 
the economic analysis would have been more favourable towards policies with planned CS. Against 
this should be weighted the research that has shown that caesarean section is associated with 
increased risk of a range of complications in subsequent pregnancies.34-36 These risks are not 
captured in our simulation model since the perspective was for the current pregnancy, but implies 
that managing suspected macrosomia through planned CS may be more detrimental than suggested 
in this analysis. 
This analysis has compared interventions based upon suspicion of macrosomia alone. However, in 
clinical practice more factors influence antenatal management than just whether ultrasound 
screening indicates fetal macrosomia. This analysis offer valuable information for policymaking, but 
it does not rule out the use of planned CS or expectant management in individual cases. 
 
Conclusion 
Universal ultrasound scanning in the third trimester is not cost-effective at detecting macrosomia in 
nulliparous women at current UK cost-effectiveness threshold limits. If fetal macrosomia is 
suspected following ultrasound, induction of labour is likely to be the most cost-effective 
management option. 
The conclusions are based on a single scan for macrosomia alone. A strategy that combines scanning 
for macrosomia with other conditions, e.g. breech presentation (and growth restriction), might be 
cost-effective. Future research should focus on whether joint screening for multiple fetal 
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complications would be cost-effective, as well as on the long-term health consequences from 
delivery outcomes, especially how maternal health is affected by the mode of delivery. 
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Tables & Figures 
Figure 1: Structure of simulation model. 
The figure shows the model structure, from screening to long-term health outcomes. Part A (left) 
shows the pathway from screening to the mode of delivery. When macrosomia is suspected (“T+”), 
the mode of delivery depends on the management strategy as shown in part B (middle). Part C (right) 
shows the different delivery outcomes, and their associated long-term outcomes. 
CS = Caesarean section; BPI = Brachial plexus injury; D+ = disease positive; D- = Disease negative; T+ = 
Test positive; T- = Test negative. 
 
Figure 2: Cost-effectiveness acceptability curve for policies for detection and management of fetal 
macrosomia. 
Cost-effectiveness acceptability curve (CEAC) showing the chance for each policy of being the most 
cost-effective for different levels of willingness-to-pay (WTP). Policies with universal ultrasound are 
shown as dashed lines and selective ultrasound as solid. Higher values for WTP implies a higher 
valuation of a quality-adjusted life year (QALY). The conventional WTP-thresholds for cost-
effectiveness is £20,000 to £30,000 (marked in figure).29 
CS = Caesarean section.  
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Table 1: Expected costs and QALYs per screening and management strategy. 
Strategy Cost (95% CI)) QALY (95% CI) † ICER NMB (95% CI) 
Selective ultrasound + expectant 2821 (2409, 3236) 27.441 (27.262, 27.621) - 546007 (542803, 549204) 
Selective ultrasound + induction 2826 (2412, 3242) 27.446 (27.267, 27.626) 904 546098 (542890, 549298) 
Selective ultrasound + planned CS 2833 (2436, 3230) 27.417 (27.244, 27.588) Dominated 545501 (542424, 548561) 
Universal ultrasound + expectant 2933 (2502, 3366) 27.441 (27.261, 27.621) Dominated 545884 (542695, 549070) 
Universal ultrasound + induction 2939 (2506, 3374) 27.448 (27.268, 27.628) 52719 546028 (542829, 549214) 
Universal ultrasound + planned CS 2955 (2549, 3360) 27.396 (27.224, 27.565) Dominated 544956 (541919, 547978) 
Options ordered from lowest to highest expected cost.  ICERs calculated beginning with least expensive option, and comparing with next most expensive, 
non-dominated option; a policy was dominated / extended-dominated if any other policy or weighted average of two policies was associated with both 
lower costs and higher QALYs.  Net monetary benefit (NMB) was calculated using a Willingness-To-Pay (WTP) threshold of £20,000; higher NMB value 
means greater cost-effectiveness. Option with the highest expected net monetary benefit highlighted in bold.  All costs and NMB are given in pounds 
sterling (£). CS = Caesarean section; QALY = Quality adjusted life-year; ICER = Incremental cost-effectiveness ratio; NMB = Net monetary benefit. 
† The maximum QALYs for two people over 20 years, discounted at 3.5%, is 29.42. 
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Figure 1: Structure of simulation model. 
 
The figure shows the model structure, from screening to long-term health outcomes. Part A (left) 
shows the pathway from screening to the mode of delivery. When macrosomia is suspected (“T+”), 
the mode of delivery depends on the management strategy as shown in part B (middle). Part C (right) 
shows the different delivery outcomes, and their associated long-term outcomes. 
CS = Caesarean section; BPI = Brachial plexus injury; D+ = disease positive; D- = Disease negative; T+ = 
Test positive; T- = Test negative. 
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Figure 2: Cost-effectiveness acceptability curve for policies for detection and management of fetal 
macrosomia. 
 
Cost-effectiveness acceptability curve (CEAC) showing the chance for each policy of being the most 
cost-effective for different levels of willingness-to-pay (WTP). Policies with universal ultrasound are 
shown as dashed lines and selective ultrasound as solid. Higher values for WTP implies a higher 
valuation of a quality-adjusted life year (QALY). The conventional WTP-thresholds for cost-
effectiveness is £20,000 to £30,000 (marked in figure).29 
CS = Caesarean section. 
 
